ÂÜÀòÂÒÂ×

Dr. Gibson is Chief Scientific Officer of COI Pharmaceuticals. In this role, he is responsible for the creation of new biotechnology companies that advance innovative therapeutics into areas of high unmet medical need. He is currently serving as CEO for Adanate and Chief Scientific Officer for PDI Therapeutics and Silarus Therapeutics. Dr. Gibson has more than 30 years of drug development experience and has been involved in the successful discovery, development and commercialization of four approved oncology drugs (temozolomide, sorafenib, erlotnib, and crizotinib). Dr. Gibson has held numerous senior positions within the biotechnology and pharmaceutical industry, including Chief Scientific Officer of Regulus Therapeutics, Chief Scientific Officer and Oncology Therapeutic Area Head at Pfizer Oncology, and Chief Scientific Officer at OSI Pharmaceuticals. Dr. Gibson has also held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute. Dr. Gibson earned his Ph.D. in 1982 from the University of Aston.